| Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer JP Neijt, SA Engelholm, MK Tuxen, PG Sørensen, M Hansen, C Sessa, ... Journal of Clinical Oncology 18 (17), 3084-3092, 2000 | 601 | 2000 |
| Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. H Anderson, B Lund, F Bach, N Thatcher, J Walling, HH Hansen Journal of Clinical Oncology 12 (9), 1821-1826, 1994 | 491 | 1994 |
| Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer patients B Lund, OP Hansen, K Theilade, M Hansen, JP Neijt JNCI: Journal of the National Cancer Institute 86 (20), 1530-1533, 1994 | 418 | 1994 |
| Topoisomerase I inhibitors: topotecan and irenotecan GJ Creemers, B Lund, J Verweij Cancer treatment reviews 20 (1), 73-96, 1994 | 310 | 1994 |
| Clinical and preclinical activity of 2′, 2′-difluorodeoxycytidine (gemcitabine) B Lund, PEG Kristjansen, HH Hansen Cancer treatment reviews 19 (1), 45-55, 1993 | 166 | 1993 |
| Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor J Verweij, B Lund, J Beijnen, A Planting, M de Boer-Dennert, I Koier, ... Annals of oncology 4 (8), 673-678, 1993 | 143 | 1993 |
| Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. L Sengeløv, C Kamby, B Lund, SA Engelholm Journal of clinical oncology 16 (10), 3392-3397, 1998 | 102 | 1998 |
| High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. B Lund, M Hansen, OP Hansen, HH Hansen Journal of Clinical Oncology 7 (10), 1469-1473, 1989 | 78 | 1989 |
| Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients B Lund, OP Hansen, JP Neijt, K Theilade, M Hansen Anti-Cancer Drugs 6, 61-62, 1995 | 71 | 1995 |
| Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. B Lund, M Hansen, F Lundvall, NC Nielsen, BL Sørensen, HH Hansen Surgery, gynecology & obstetrics 169 (3), 213-218, 1989 | 71 | 1989 |
| Phase I Study of Single, Escalating Doses of a Superantigen—Antibody Fusion Protein (PNU-214565) in Patients With Advanced Colorectal or Pancreatic Carcinoma SE Nielsen, J Zeuthen, B Lund, B Persson, J Alenfall, HH Hansen Journal of Immunotherapy 23 (1), 146-153, 2000 | 55 | 2000 |
| Correlation of abdominal ultrasound and computed tomography scans with second-or third-look laparotomy in patients with ovarian carcinoma B Lund, K Jacobsen, L Rasch, F Jensen, K Olesen, K Feldt-Rasmussen Gynecologic oncology 37 (2), 279-283, 1990 | 53 | 1990 |
| Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications B Lund, HK Thomsen, J Olsen Apmis 99 (1‐6), 353-358, 1991 | 49 | 1991 |
| Gemcitabine in cisplatin-resistant ovarian cancer B Lund, JP Neijt Seminars in oncology 23 (5 Suppl 10), 72-76, 1996 | 43 | 1996 |
| Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma B Lund, P Williamson, HC van Houwelingen, JP Neijt Cancer research 50 (15), 4626-4629, 1990 | 42 | 1990 |
| Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease. B Lund, M Hansen, OP Hansen, HH Hansen Journal of Clinical Oncology 8 (7), 1226-1230, 1990 | 40 | 1990 |
| Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma B LUND, P WILLIAMSON Obstetrics & Gynecology 76 (4), 617-622, 1990 | 39 | 1990 |
| The role of second-look laparotomy in the long-term survival in ovarian cancer MK Tuxen, G Strauss, B Lund, M Hansen Annals of oncology 8 (7), 643-648, 1997 | 36 | 1997 |
| Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. JP Neijt, SA Engelholm, PO Witteveen, MK Tuxen, PG Sørensen, ... Seminars in oncology 24 (5 Suppl 15), S15-36, 1997 | 34 | 1997 |
| Phase II study of gemcitabine (2', 2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer B Lund, M Ryberg, PM Petersen, H Anderson, N Thatcher, ... Annals of oncology: official journal of the European Society for Medical …, 1994 | 34 | 1994 |
